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ABSTRACT:
Antisense oligonucleotides provide a promising therapeutic approach for several disorders including cancer. Chemical stability,
controlled release, and intracellular delivery are crucial factors determining their eﬃcacy. Gels composed of nanoﬁbrous peptide
network have been previously suggested as carriers for controlled delivery of drugs to improve stability and to provide controlled
release, but have not been used for oligonucleotide delivery. In this work, a self-assembled peptide nanoﬁbrous system is formed by
mixing a cationic peptide amphiphile (PA) with Bcl-2 antisense oligodeoxynucleotide (ODN), G3139, through electrostatic
interactions. The self-assembly of PA-ODN gel was characterized by circular dichroism, rheology, atomic force microscopy (AFM)
and scanning electron microscopy (SEM). AFM and SEM images revealed establishment of the nanoﬁbrous PA-ODN network.
Due to the electrostatic interactions between PA and ODN, ODN release can be controlled by changing PA and ODN
concentrations in the PA-ODN gel. Cellular delivery of the ODN by PA-ODN nanoﬁber complex was observed by using
ﬂuorescently labeled ODN molecule. Cells incubated with PA-ODN complex had enhanced cellular uptake compared to cells
incubated with naked ODN. Furthermore, Bcl-2mRNA amounts were lower inMCF-7 human breast cancer cells in the presence of
PA-ODN complex compared to naked ODN andmismatch ODN evidenced by quantitative RT-PCR studies. These results suggest
that PA molecules can control ODN release, enhance cellular uptake and present a novel eﬃcient approach for gene therapy studies
and oligonucleotide based drug delivery.
1. INTRODUCTION
Use of antisense oligonucleotides as inhibitors to regulate
expression of speciﬁc genes is a promising approach for treat-
ment of diseases such as cancer and infectious and inﬂammatory
diseases.1,2 Antisense therapy has important advantages such as
target speciﬁcity and reduced side eﬀects. In theory, antisense
molecules can be designed to inhibit expression of any gene.3
However, stability of these oligonucleotides in plasma is a pro-
blem, and there is ongoing research to improve their stability.
Chemically modiﬁed oligonucleotides have improved stability,
however, when they are not combined with proper delivery
agents, they have limited ability to cross the cell membrane due to
their charge and highmolecular weight.4,5 Thus, eﬀective delivery
systems are necessary for enhanced cellular uptake. To achieve
sustained pharmacological activity of oligonucleotides and to
avoid multiple administrations, several release and delivery
systems based on biodegradable polymers or lipids have been
suggested such as cationic liposomes,6,7 synthetic biodegradable
polymers, nano or microparticles (polylactide-co-glycolide micro-
particles),8,9 hydrogels (PLA-b-PEG-b-PLA hydrogel),10 micelles
(polylactidepolyethylene glycol copolymers),11 ﬁbrous scaf-
folds (electrospun polyethylene covinylacetate), polylactic acid,12
and cationic polymers (polyethylenimine,13 polylysine,14 cationic
facial amphiphiles15). These nonviral delivery systems are usually
hydrophilic and positively charged.16 Nonviral delivery vectors
constructed with biodegradable materials are preferred over viral
delivery vehicles due to side eﬀects of the latter such as non-
speciﬁc toxicity and low performance in serum.17 The nonviral
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systems mentioned above decrease enzymatic degradation of
chemically unmodiﬁed oligonucleotides and partially increase
their cellular uptake. However, these systems are generally
diﬃcult to use and mostly do not work in serum containing
media. Furthermore, highly positively charged polymers such as
polyethylenimine (PEI) cause cellular toxicity.18
Peptide amphiphiles (PAs), which are composed of a hydro-
phobic site, a β-sheet forming short peptide sequence, a hydro-
philic peptide sequence, and a bioactive peptide group, are pro-
mising tools for drug and gene delivery systems because they are
biocompatible and bioactive. PA molecules form highly ordered
nanostructures through self-assembly. Hydrophobic site of PA
molecules, composed of a long alkyl chain, induces hydrophobic
collapse and remains in the interior part of the nanoﬁber struc-
ture. Hydrophilic peptide segment enables solubility in water
and presents bioactive peptide sequence on the surface of the
self-assembled nanostructures.19,20 The β-sheet structures are
formed through intermolecular hydrogen bonding between pep-
tides, oriented parallel along the axis of the well-deﬁned, one-
dimensional nanoﬁber structure.2023 The addition of oppositely
charged molecules such as biomacromolecules (e.g., DNA, pro-
tein, polysaccharides), divalent ions or change in pH trigger
spontaneous nanoﬁber assembly of PAs through charge screen-
ing. Water absorption by the mesh-like network formed by these
nanoﬁbers results in gel structure.24 Chemical, physical, and
biological properties of nanoﬁbers can be controlled by non-
covalent bonds and supramolecular interactions.25 Gels formed
by PAs have been used for various applications including drug
delivery. They were functionalized to release proteins such as
sonic hedgehog (SHH) protein26 or to deliver growth factors
(e.g., bone morphogenic protein factor-227 and ﬁbroblast growth
factor28). PA nanoﬁbers were also employed to deliver and
encapsulate hydrophobic drugs including pyrene,29 doxorubicin,30
and cisplatin.31
Positively charged carrier systems for oligonucleotide delivery
have been used to provide eﬀective cellular uptake through en-
hanced binding to negatively charged proteoglycans on the cell
surface.32,33 Besides, hydrophobic content of the PA molecules
facilitates internalization through cell membrane.34 In this study,
the hydrophilic lysine residues were chosen to bind to oligonu-
cleotides and form nanoﬁbers at physiological pH upon addition
of oligonucleotides through charge screening. An amphiphilic
peptide forming β-sheet structure with four nonpolar amino acid
residues and positively charged lysine residue at physiological
conditions was designed and synthesized to interact with oligo-
nucleotides. Polyamine groups presented on the surface of the self-
assembled nanoﬁbers provide a positive charge at physiological pH
that can facilitate uptake of PA-oligonucleotide complexes.35,36
Oligonucleotides can be released by degradation of the biode-
gradable peptide scaﬀold or by physical release mechanisms
governed by diﬀusion. Cells can uptake nanoﬁbers degraded by
proteases and use them in their metabolic pathways showing
biocompatibility of PAs.37
Herein, we demonstrate self-assembled nanoﬁber formation
of a PA system with an oligonucleotide as a slow release and
delivery system. We demonstrate a new carrier system to deliver
G3139 as an antisense oligonucleotide drug model. G3139
(Genasense, Genta Inc., NJ) is a chemically modiﬁed 18-mer
phosphorothioate antisense oligodeoxynucleotide (ODN), de-
signed to bind to the ﬁrst six initiation codons of the Bcl-2
mRNA.38 Bcl-2 protein family is crucial for mediating controlled
cell death andoverexpression ofBcl-2protein leads to accumulation
of aged and damaged cells resulting in tumor formation. Bcl-2 has
been associated with many aggressive tumor phenotypes.39
G3139 has been shown to eﬀectively reduce both Bcl-2 mRNA
and protein expression and induce programmed cell death.40
G3139 has been in clinical trials since 1995 in the U.S.A., Europe
and Australia, with eﬃcacy and safety data from phases 1, 2, and
3 clinical trials. G3139 is now being evaluated clinically in
treatment of melanoma, chronic lymphocytic leukemia, and
other tumors in combination with many types of anticancer
therapies.4143
In this study, we used a cationic peptide amphiphile molecule,
Lys-PA (C12-VVAGK-Am), as a nonviral antisense oligonucleo-
tide carrier and delivery system. Controlled release of ODN from
PA-ODN system, ODN internalization by cells and eﬀects of this
nanocarrier system on Bcl-2mRNA levels are demonstrated. We
illustrated that PA and ODNmolecules form nanoﬁbers through
charge screening by using circular dichroism, SEM, and AFM
imaging. We showed that PA-ODN assembly provides con-
trolled release of ODN from peptide nanoﬁbers, enhanced
intracellular accumulation of ODN and downregulation of Bcl-
2 mRNA.
2. EXPERIMENTAL SECTION
2.1.1. Materials. 9-Fluorenylmethoxycarbonyl (Fmoc) and tert-bu-
toxycarbonyl (Boc)-protected amino acids, [4-[R-(20,40-dimethoxy-
phenyl)Fmoc-aminomethyl]phenoxy]acetamidonorleucyl-MBHA re-
sin (Rink amide MBHA resin), and 2-(1H-benzotriazol-1-yl)-1,1,3,
3-tetramethyluronium hexafluorophosphate (HBTU) were purchased
from NovaBiochem and ABCR. DMEM media, fetal bovine serum
(FBS), trypsin EDTA, and penicillin/streptomycin were purchased
from Invitrogen.
2.1.2. Antisense Oligonucleotides. G3139, a phosphorothioate oli-
godeoxynucleotide (Genasense), with a sequence complementary for
the first six codons of the open reading frame of Bcl-2mRNA: 50-tct ccc
agc gtg cgc cat-30 (18-mer) was used as the antisense ODN. A two-base
mismatched (MM) sequence, G4126, 50-tct ccc agc atg tgc cat-30, was
used as control and G3139 labeled with 6-fluorescein on the 50-t, G4243,
50-tac cgc gtg cga ccc tct-30, was used in cell internalization assays. ODNs
were donated by Genta Inc. (Genta Inc., NJ).
2.1.3. Cells.The human breast cancer cell lineMCF-7 (American Type
Culture Collection) was maintained in low glucose DMEM (GIBCO)
supplemented with 10% FBS, 100 μg/mL streptomycin, and 100 μg/mL
penicillin at 37 C in a humidified incubator with 5% CO2.
2.2. Peptide Synthesis, Purification, and Characterization.
2.2.1. Synthesis of Peptide Amphiphiles. Lauryl-VVAGK peptide (Lys-
PA) was constructed on MBHA Rink Amide resin at 0.25 mmol scale.
Amino acid couplings were done with 2 equiv of Fmoc-protected amino
acid, 1.95 equiv ofHBTU, and 3 equiv ofDIEA for 2 h. Fmoc removal was
performed with 20% piperidine/dimethylformamide (DMF) solution for
20 min. Cleavage of the peptides from the resin was carried out with a
mixture of TFA:TIS:H2O in the ratio of 95:2.5:2.5 for 3 h. ExcessTFAwas
removed by rotary evaporation. The remaining viscous peptide solution
was triturated with ice-cold ether and the resulting white product was
freeze-dried. Peptide was characterized by liquid chromatographymass
spectrometry (LC-MS). Its purity was observed to be over 95% by LC
chromatogram (Figures S1 and S2). Mass spectrum was obtained with
Agilent LC-MS equipped with Zorbax SB-C8 4.6  100 mm column. A
gradient of (a) water (0.1% formic acid) and (b) acetonitrile (0.1% formic
acid) was used for LC-MS characterization. Peptide purification was
performed with a Zorbax prepHT 300SB-C8 column with water
acetonitrile (0.1% TFA) gradient.
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2.2.2. Circular Dichroism (CD) Measurement. JASCO J815 CD
spectrapolarimeter was used at RT to analyze secondary structures in
400 μL of peptide solution alone at a final concentration of 3.8 104M
andmixture of peptide (3.8 104 M final) and ODN (3.125 μM final)
solutions at wavelengths ranging from 260 to 190 nm, data interval and
data pitch being 0.1 nm, scanning speed being 100 nm/min. All
measurements were done with three accumulations. DIT was selected
as 1 s, bandwidth as 1 mm, and the sensitivity was standard.
2.2.3. Viscoelasticity and Gelation Behavior. Gelation behaviors of
the ODN and Lys-PA gels were evaluated by an Anton Paar Physica
RM301 Rheometer operating with a 25 mm parallel plate configuration
at 25 C. Each sample with 100 μL of total volume with a final peptide
concentration of 1 wt % and ODN solutions with different concentra-
tions was carefully loaded on the center of the lower plate and incubated
for 15min before performing rheometry analysis. After equilibration, the
upper plate was lowered to a gap distance of 0.5 mm. Storage moduli
(G0) and loss moduli (G00) values were measured from 100 rad/s to
0.1 rad/s of angular frequency with 0.5% shear strain.
2.2.4. Morphological Observation. Three-dimensional network of
the nanofibrous gel was observed by atomic force microscopy (AFM)
and scanning electron microscopy (SEM).
2.2.4.1. Atomic Force Microscopy (AFM). AFM sample was pre-
pared by mixing 0.02 wt % PA and ODN solution in H2O. After in-
cubation for 30min at RT, themixture was diluted 20 inH2O to obtain
0.5 μM ODN concentration. Final solution was drop-casted and dried
on a freshly cleaved silicon wafer. AFM images were recorded using
model MFP-30 from Asylum Research operated in tapping mode at a
frequency of 246 kHz. AFM images were taken at 1024  512 pixels
resolution. Image was taken with spring constant 40 N/m and the set
point and scanning speed were 0.71.0 V and 1.01.5 Hz, respectively.
2.2.4.2. Scanning ElectronMicroscopy (SEM).A 3D network of self-
assembled 100 μL gels were prepared on a metal mesh by mixing 50 μL
of 1 wt % PA solution in H2O with 50 μL of ODN solution in PBS (1,
pH 7.4) containing 250 ng/μL of ODN. Water was exchanged with
ethanol gradually in water/ethanol mixtures of increasing ethanol
concentrations and finally in 100% ethanol for 30 s at each step. Gel
was dried at critical point (1072 psi, 31 C) with Tousimis Autosamdri-
815B, Series C critical point dryer and coated with 10 nm AuPd.
Sample was imaged by a FEI Quanta 200 FEG, using the ETD detector
at high vacuum mode at a voltage of 30 keV.
2.3. ODN Release from PA-ODN Gel. ODN release from PA-
ODN gel was examined by diluting Lys-PA with H2O to 2 wt % in 50 μL
andmixing with 50μL ofODNsolution (30μg/μL and 2μg/μL) in PBS
(1, GIBCO) to obtain a final 1 wt % peptide gel containing 15 μg/μL
and 1 μg/mL ODN. After 15 min incubation, 100 μL of 1 PBS was
added onto gel. ODN release was measured by NanoDrop (The
Thermo Scientific NanoDrop 2000, U.S.A.) at 260 nm for a period of
6 days for gel formed with 30 μg/μL ODN and 3 days for gel formed
with 2 μg/μL ODN solution. To examine the effect of PA and ODN
concentration on release profile of ODN; 100 μL of gels were formed
using ODN with concentrations of 1501200 ng/μL and PA with
concentrations of 0.20.1 wt%. The gels were prepared in 96-well plates
and incubated for 1 h at 37 C followed by overnight drying in a laminar
flow hood. Next day, 100μL of PBS (1) was added on coated wells and
gels were maintained at 37 C for a period of 5 days during ODN
concentration analysis. To see burst release, 2 μL aliquots from PBS
solution were measured in short time intervals during the first day and
every 24 h afterward. A total of 2 μL of fresh buffer was added to wells
after each measurement for all experiments. ODN release versus time
was graphed according to initial concentration of ODN trapped in the
gel. Three replicates were tested for each PA and ODN formulation.
2.4. Cellular Uptake of PA-ODN Complexes. MCF-7 breast
cancer cells (3  104 cells/well) were plated in 0.5 mL of growth
medium on coverslips in 24-well chambered plates and grown overnight.
On the following day, the cells were treated with 20 μL of mixture with an
equal volumeof Lys-PA andFAM-labeledODN(G3139) or 10μLof FAM
labeled ODN alone for 4 h. Mixture of FAM labeled ODN (30 ng/μL)
in PBS and 0.01 wt % Lys-PA in H2O was prepared by gently mixing
ODNs and PAs to achieve a molar ratio of 30:1 (Lys-PA/ODN), fol-
lowed by incubation for 30 min at RT. After 4 h incubation, cells were
rinsed three times with PBS, fixed with 4% paraformaldehyde and
stained with 1 μg/mL solution of TO-PRO-3 (Invitrogen) for nuclei
staining. To see the distribution of the PA-ODN complex in cell cyto-
plasm, after a 4 h incubation with FAM-labeled ODN alone or PA-ODN
mixture, cell culture medium was removed, 500 μL/well fresh cell cul-
ture medium was added, and cells were incubated for an additional 44 h.
Cells were imaged by a laser scan confocal microscope (ZEISS LSM 510
META, ZEISS GmbH, Jena, Germany).
2.4.1. Cell Viability and Proliferation Assay. The cytotoxicity of the
ODN, PA, and PA-ODN complexes was measured by MTT [3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide] assay (Sigma).
MCF-7 cells were plated on 96-well plates at a density of 3 103 cells/
well and grown overnight. Next day, the cells were treated with either a 5
μL mixture of equal volumes of Lys-PA (0.02 wt %) and ODN/MM-
ODN or a 2.5 μL of 1 μM solution of ODN/MM-ODN alone. After
incubation at 37 C for 4 h, cell culture medium was replaced with fresh
medium followed by additional 44 h incubation. MTT assay was per-
formed according to the manufacturer’s protocol. Briefly, media on cells
were aspirated and 100 μL fresh media containing 10% (v/v) recon-
stitutedMTT (M-5655) reagent was added to each well. The plates were
incubated for 3 h and the absorbance of the medium was measured at
570 nm with plate reader (SpectraMax M5, Molecular Devices). The
background absorbance of multiwell plates were also measured at
690 nm and subtracted from the 570 nm measurement.
To conﬁrm the eﬀect of PA-ODN complex on proliferation ofMCF-7
cells, the BrdU cell proliferation kit (Roche) was used. Cells were seeded
at a density of 3000 cells/well in a ﬁnal volume of 100 μL in 96-well
culture dishes and incubated overnight. The cells were treated with
either a 5μLmixture of equal volumes of Lys-PA (0.02 wt%) andODN/
MM-ODN or a 2.5 μL solution of ODN/MM-ODN alone with 1 μM
ﬁnal concentration. After incubation at 37 C for 4 h, cell culture
medium was changed with fresh medium followed by additional 20 h
incubation. Next, 10 μL of 100 μM BrdU label was added to each well
and incubated for an additional 24 h at 37 C. The labeling medium was
removed by tapping oﬀ and replaced with 200 μL of ﬁx/denaturing
solution followed by a 30 min incubation at RT. The ﬁx/denaturing
solution was removed thoroughly by ﬂicking oﬀ and tapping. A total of
100 μL/well anti-BrdU-POD working solution was added to each well
and left for 90 min at RT. Antibody conjugate was removed by ﬂicking
oﬀ and wells were rinsed 3 times with 200300 μL/well with washing
solution (PBS, 1). Finally, 100 μL/well of substrate solution was added
into wells and incubated at RT until color development is suﬃcient for
photometric detection (30 min). Absorbance (A370A492 nm) of the
samples was measured with plate reader (SpectraMax M5, Molecular
Devices). Absorbance values were normalized with respect to cells
incubated without ODN drug. Assays were carried out in triplicate.
2.4.2. Determination of Bcl-2 mRNA Expression by Quantitative RT-
PCR.MCF-7 breast cancer cells were plated in six-well plates containing
2 mL of media. Following overnight growth at 37 C in a humidified
incubator with 5% CO2, cells were treated with either a 100 μL mixture
of equal volumes of Lys-PA (0.02 wt %) and ODN/MM-ODN or a
50 μL solution of ODN/MM-ODN alone with 1 μM final concentra-
tion. After incubation at 37 C for 4 h, cell culture medium was changed
with fresh medium followed by additional 44 h incubation. The PA-
ODN complexes were prepared by mixing equal volumes of ODN
solution in PBS (1, GIBCO) and Lys-PA (0.02 wt %) in ddH2O and
incubated for 30 min at RT before adding 5 μL of this mixture onto cells.
After 4 h incubation withODN,mismatchODNor their complexes with
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Lys-PA, medium was replaced with fresh cell medium. Total RNA was
extracted from cells after 48 and 72 h incubations by using Trizol reagent
(Invitrogen). RNA concentration was measured with NanoDrop spec-
trophotometer (Thermo Scientific NanoDrop 2000, USA) at 260 nm.
The Bcl-2mRNA expression level was measured by using quantitative
RT-PCR with SuperScript III Platinum SYBR Green One-Step qRT-
PCR Kit (Invitrogen). Samples were incubated in C1000TM thermal
cycler (CFX96 real Time systems, Bio-RAD). After cDNA synthesis for
3 min at 50 C, cDNA denaturation was carried out for 5 min at 95 C
followed by denaturation at 95 C for 15 s and annealing at 60 C for
30 s. Primer sequences were designed by using DNASTAR Lasergene 8
program. The following primer pairs were used for qRT-PCR experi-
ments: 50-tgc ccc tgt gga tga ctg ag-30 and 50-gtt tgg ggc agg cat gtt gac t-30
for Bcl-2 and 50-tcg aca gtc agc cgc atc ttc t-30 and 50-gtg acc agg cgc cca
ata cga c-30 for GAPDH. Relative gene expression values were deter-
mined by the Pfaﬄmethod. GAPDH was used as housekeeping gene to
normalize the gene expression levels of each sample.
2.4.3. Western Analysis.MCF-7 breast cancer cells were plated in six-
well plates containing 2 mL of media. Following overnight growth at
37 C in a humidified incubator with 5% CO2, cells were treated with
either a 100 μL mixture of equal volumes of Lys-PA (0.02 wt %) and
ODN/MM-ODN or a 50 μL solution of ODN/MM-ODN alone with a
final concentration of 1 μM. After incubation at 37 C for 4 h, cell cul-
ture medium was changed with fresh medium followed by additional
68 h incubation. The complexes of PA-ODN were prepared by mixing
equal volumes of ODN solution in PBS (1, GIBCO) and Lys-PA
(0.02 wt %) in ddH2O and incubated for 30 min at RT before adding of
this mixture onto cells. After 72 h incubation, MCF-7 cells were washed
with 1 PBS and lysed with 100 μL of 1 SDSsample buffer. The
extract was transferred to a microcentrifuge tube and centrifuged at
13000g for 10 min at 4 C. The supernatant was collected to a fresh tube
and the total protein concentration was determined by using BCA
protein assay (Pierce, Rockford, IL). Cell lysates containing 50 μg of
total protein were loaded and separated on a 10% SDS-polyacrylamide
gel at 150 V for 1.5 h. After blotting (trans-blot SD, Semi Dry transfer
cell, Bio-Rad) to polyvinylidine difluoride membranes (Thermo Scien-
tific) at 14 V for 35 min, the membrane was blocked in a solution of
5% powdered nonfat milk in Tris-buffered saline/Tween-20 followed
by incubation with monoclonal anti-Bcl-2 clone 100 (Millipore; 1:1000)
or monoclonal anti-β-Actin antibody (1:5000; Sigma-Aldrich). After
washing with milk, the membranes were incubated with horseradish
peroxidase conjugated goat antimouse secondary antibody (Millipore)
(1:2000). The membranes were developed with Novex Chemilumines-
cent Substrates (Invitrogen) and observed with Kodak Biomax NS film.
3. RESULTS AND DISCUSSION
Lauryl-VVAGK-Am (Lys-PA) peptide was synthesized by
utilizing solid phase peptide synthesis method (Figures S1 and
S2). Lauric acid provides amphiphilicity with its hydrophobic
character that triggers peptide molecules to self-assemble into
nanoﬁbers. The β-sheet forming group consists of four nonpolar
amino acid residues. Lysine residue provides water solubility and
a cationic feature which triggers gel formation upon mixing with
negatively charged oligonucleotides (Figure 1a). Characteriza-
tion of PA-ODN gels by AFM and SEM imaging revealed their
Figure 1. (a) Schematic representation of Lys-PA and ODN (50-tct ccc agc gtg cgc cat-30) nanoﬁbers. (b, c) AFM topography and SEM images of the
nanoﬁber network reveal nanoﬁbrous 3-D network of the PA-ODN complex. (d) CD spectra demonstrate increased β-sheet formation in PA-ODN
mixture compared to PA alone.
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3-D nanoﬁbrous network structure (Figure 1b,c). Lys-PAs self-
assemble into nanoﬁbers upon addition of oppositely charged
ODN through charge screening and three-dimensional network
of these nanoﬁbers results in gel formation upon water encapsu-
lation. Network formation is critical for drug release since it en-
ables physical encapsulation of the drug in addition to electro-
static interactions between the ODN and PA molecules. In
addition, ODN release is dependent on electrostatic interactions
between the PAs and ODNs. Therefore, PA degradation can also
be responsible for additional ODN release in vitro and in vivo.
Secondary structures of the nanoﬁbers formed through charge
neutralization of the PA molecules by mixing with ODNs were
analyzed by circular dichroism (CD). CD spectroscopy at dif-
ferent concentrations of ODNs demonstrated PAs forming pre-
dominantly β-sheet structure at a concentration of 3.8 104M.
The β-sheets display a negative minimum at 218 nm and a
positive ellipticity at 195 nm.44 CD spectrum of PA without
ODN at the same concentration revealed a mixture of random
coil andβ-sheet structures.45 The amount ofβ-sheet structures in
PA alone samples was much lower compared to CD spectrum of
PA with ODN (Figure 1d).
Encapsulation of water by the 3-D nanoﬁbrous network re-
sulted in gel formation triggered by addition of ODN solution as
demonstrated by oscillatory rheology. G0 and G00 did not change
with angular frequency from 100 to 0.1 rad/s (Figure S3). As we
increased the ODN amount, storage moduli (G0) of samples
increased and became signiﬁcantly higher than their loss moduli
(Figure 2). G0/G00 was higher than 1, a critical point of gelation,
which indicates PA-ODN gel behaves like an elastic solid.24
We evaluated the eﬀect of the Lys-PA and ODN concentra-
tions on the release of ODN through release assays. The nano-
ﬁbrous nature of the PA-ODN system enables physical encapsu-
lation of the ODN as well as increasing the physical interaction
between the PA and ODN molecules. The release proﬁle of
ODN from gel prepared (Figure S4) by mixing 50 μL of 2 wt %
Lys-PA and 50 μL of 30 μg/μL ODN is shown in Figure 3. We
monitored sustained release of ODN from 3-D PA-ODN nano-
ﬁbrous network while the majority of ODN (8090%) was
released by 6 days (Figure 3). Eﬀect of charge ratio is an im-
portant factor that determines the strength of the electrostatic
interactions and it was further studied by changing peptide con-
centration in the PA-ODN gels. For this purpose, ODN release
was studied with a gel of 2 μg/μL (2000 ng/μL) ODN and
2 wt % Lys-PA for 3 days (Figure S5). Release of ODN from gel
formed with 30 μg/μL ODN solution was around 55% by day 3
while release of ODN from gel formed with 2 μg/μL ODN was
around 15% with a slower release proﬁle. In addition, Figure 4
demonstrates that ODN release from gel decreased as the pep-
tide concentration was increased due to enhanced attraction of
anionic ODNs by the cationic nanoﬁbrous network. The average
release proﬁle was also aﬀected by the concentration of ODN in
gel, where the higher the ODN concentration, the higher ODN
release from gel was observed due to insuﬃcient attraction by
cationic Lys-PAs on anionic ODNs in the gel. At low ODN
concentrations (150 ng/μL and 300 ng/μL in Figure 4a,b,
respectively), 66% of the initial amount of ODN was trapped
in the 0.1 and 0.2 wt % Lys-PA-ODN gels and release from the
3-D network was slow for all three concentrations of PAs. Release
assay from the gels with 600 ng/μL ODN concentration showed
rapid initial release within the ﬁrst 3 h when 0.1 wt % gel was used
whereas slower release proﬁles were observed from 0.15 wt %
and 0.2 wt % gels (Figure 4c). When a higher concentration
(1200 ng/μL) of ODN was used for release assays, rapid initial
release within the ﬁrst 3 h was observed for all three PA
concentrations (Figure 4d). After 2 days, release proﬁle reached
plateau values for all formulations. When same PA concentration
was used for encapsulating diﬀerent concentrations of ODN,
using lower concentrations of ODN resulted in slower release
while as ODN concentrations were increased, more rapid initial
release proﬁles were observed (Figure S6). Antisense oligonu-
cleotides are not only localized on the surface of the nanoﬁbers
through electrostatic interactions between positively charged PA
molecules and negatively charged ODNs but also physically
encapsulated inside the peptide nanoﬁber network. The initial
burst release is due to weaker interactions between the ODNs
and the PAs which is caused by physical encapsulation. The latter
slow release is likely to be caused by stronger bonds caused by
electrostatic interactions between the PA and ODN molecules.
Therefore, self-assembled PA and ODN nanoﬁbers can be used
for controlled ODN release by changing PA/ODN charge ratio
and the PA-ODN nanoﬁber network provides a promising tool
for controlled release of oligonucleotides. It is known that
oligonucleotides have short half-lives in the body. Consequently,
agent-free antisense ODN (G3139) is generally applied by
continuous intravenous infusion. Thus, utilization of an eﬀective
delivery system is required to improve eﬃcacy of gene targeted
Figure 2. Storage (G0) and loss (G00) moduli of gels indicate that Lys-
PA (2 wt %) with varying concentrations of ODN form gel with
viscoelastic character conﬁrmed by greater G0 values than G00. Data
points are average of n = 3 and error bars represent standard error
of mean.
Figure 3. Release proﬁle shows that there is sustained release of ODN
from peptide nanoﬁber gel of 30 μg/μL ODN and 2 wt % PA for 6 days.
Data points are average of n = 3 and error bars represent standard error
of mean.
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therapy while providing elimination of side eﬀects in the circu-
latory system after injection.
Incorporating ODNs into self-assembled Lys-PA nanoﬁbers
also enhanced ODNs’ in vitro activity and their cellular uptake.
Intracellular distribution of PA-ODN complexes was examined
by laser scan confocal microscopy (Figure 4). MCF-7 cells were
incubated with FAM labeled PA-ODN complex and free FAM
labeled ODN for 4 h at 37 C followed by ﬁxation. In order to see
distribution of PA-ODN complexes in cell cytoplasm over time,
cells were treated with PA-ODN including media for 4 h, after
which medium was removed. Fresh cell culture medium was
added and cells were incubated for an additional 44 h before ﬁx-
ation. After 48 h, we observed that PA-ODN complexes were in-
ternalized by cells (Figure 5). The internalization of ODN by
cells continues through time, and thus, eﬀectiveness of ODN is
sustained. Stronger ﬂuorescent intensity was observed in the cells
treated with PA-ODN complex after both 4 h incubation and
48 h incubation with respect to ODN alone, indicating enhanced
cellular uptake of ODNwhen it is applied with positively charged
PA due to their amphiphilic and cationic properties.
To analyze the eﬀects of PA-ODN complex on cell viability
and proliferation, MTT viability and BrdU proliferation assays
were carried out by using MCF-7 cells. Cells incubated with PA-
ODN complex showed lower viability than cells incubated with
ODN alone which proves that the PA nanoﬁber system is an
eﬀective delivery agent. Cells treated with PA-ODN complex also
revealed lower viability compared to cells treated with PA-MM
ODN complex, which shows that the decreased viability is not
caused by the PA molecules. Proliferation assays revealed no sig-
niﬁcant diﬀerences between cells treated with ODN, MM-ODN,
PA-ODN, and PA-MM ODN. This result is consistent with
previously published data46 (Figure S7a,b).
Functional delivery of ODN with PAs was also conﬁrmed by
real time PCR analysis that revealed PA and ODN (G3139)
complex induced downregulation of the Bcl-2 mRNA. MCF-7
cells treated with PA-ODN complex (G3139) exhibited a 70%
downregulation in Bcl-2 mRNA levels when compared to treat-
ment groups with PA-mismatch ODN (G4126), ODN (G3139)
alone, and mismatch ODN (G4126) alone when a 4 h long
Figure 4. Release proﬁle of ODN from gel of 0.1, 0.15, and 0.2 wt%PA andODNat concentrations of (a) 150, (b) 300, (c) 600, and (d) 1200 ng/μL for
5 days. Release proﬁles show thatODN release depends on concentration of peptide amphiphile andODN in the gel. Data points are average of n= 3 and
error bars represent standard error of mean.
Figure 5. Representative images of MCF-7 cells treated with (A) naked
FAM labeled ODN (green); (B) FAM-labeled ODN and 0.01 wt % PA
complex for 4 h followed by an additional incubation of 44 h without
treatment at 37 C. TO-PRO-3 (blue) was used to stain the nuclei. PAs
enhanced ﬂuorescence intensity in cells signiﬁcantly. Images were taken
at 63 magniﬁcation.
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treatment was applied to cells followed by 44 h of incubation
without treatment (Figure 6). At 72 h, downregulation of Bcl-
2 mRNA levels was around 30% for cells treated with PA-ODN
complex, whichwas not signiﬁcantly diﬀerent than the other treat-
ment groups (Figure S8). The increase in Bcl-2 mRNA levels at
72 h compared to 48 h might be caused by development of
resistance by MCF-7 cells against ODN treatment, similar to
previously published data.47 All expression levels were normal-
ized to cells without any ODN treatment. These ﬁndings sug-
gest that PAs can eﬀectively deliver ODNs for gene-targeted
therapies.
The eﬀect of the Bcl-2 antisense ODN (G3139) and its two
base mismatch control (G4126) as naked and with Lys-PA on
Bcl-2 protein levels in MCF-7 cells were also examined with
Western blot analysis, however, PA-ODN complex did not reveal
any signiﬁcant diﬀerences in Bcl-2 protein levels compared to
cells incubated with only cell culture medium (Figure S9). This
result might be caused by the post-transcriptional and post-trans-
lational regulation mechanisms that are normally employed by
cells to regulate protein levels and is a matter of eﬀectiveness of
G3139 itself. Nevertheless, the reduction in Bcl-2 mRNA levels
by itself at 48 h is suﬃcient to deduce that our delivery system
enables eﬀective delivery of the ODN agent.
All in vitro experiments were carried out with serum containing
media in which most of the ODN carrier systems do not
work.18 ODNs in the PA-ODN complexes are released by
degradation of the biodegradable peptide scaﬀold. Synthesis
and application of PAs as carrier and delivery agents have
advantage of convenience in usage over other biodegradable
polymers and lipids. Due to their biocompatibility, bioactive
sequences, and highly ordered nanostructures, PA nanoﬁbers
are promising drug and gene delivery systems.
4. CONCLUSION
Development of carrier systems for controlled ODN release
and eﬃcient cellular uptake of ODNs is crucial for gene targeted
therapy. In this study, we developed a novel carrier system
consisting of peptide amphiphiles and antisense oligonucleotides
and analyzed the eﬃciency of controlled ODN release and
delivery. The cationic Lys-PA molecule self-assembled upon
addition of ODN and formed nanoﬁbrous network in which
oligonucleotides bind to peptide nanoﬁbers through electrostatic
interactions and form a stable complex. Our results demonstrate
that ODN release proﬁle depends on concentrations of the pep-
tide amphiphile and ODN in the gel due to electrostatic attr-
action between cationic and anionic groups. 3D nanoﬁber net-
work is also eﬀective in encapsulation and release of ODN in a
sustained manner. PA-ODN nanoﬁbers delivered ODN eﬃ-
ciently and enhanced cellular uptake by MCF-7 cells, which re-
sulted in downregulation of Bcl-2mRNA levels. Cationic Lys-PA
provides a new tool for slow release and delivery of ODNs for
gene targeted therapy. By combining apoptotic therapeutics and
ODN treatment, PA nanoﬁbers provide a promising tool for
cancer treatment through loading peptide amphiphile gel with
several drugs with diﬀerent mechanisms of action to enhance
apoptotic activity. PA nanoﬁbrous system oﬀers site-speciﬁc
delivery of oligonucleotides by injectable gels applied to treat-
ment site. Compared to intravenous administration, site speciﬁc
delivery is expected to cause fewer side eﬀects. In addition, this
practical system can reduce the number of drug administrations,
which cause patient discomfort and might lead to infections.
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